Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific adoptive T-cell therapy is an investigational cell-based immunotherapy developed for the treatment of opportunistic cytomegalovirus (CMV) infections in patients following hematopoietic stem cell transplantation (HSCT). The therapy involves selecting T-cells from a donor that are specifically reactive against CMV antigens. These selected cells are then infused into the recipient to restore or enhance the immune system's ability to control the viral infection, particularly when conventional antiviral treatments are ineffective or poorly tolerated. This specific study is led by Mari Dallas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CMV-specific adoptive T-cell therapy (Mari Dallas).